BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  RedHill Biopharma to Host Third Quarter 2017 Financial Results Conference Call on November 13, 2017

  The Company will host a conference call on Monday, November 13, 2017, at 9:00 am EST to review the financial results and business highlights.

  November 6, 2017

   · 

  5 min read
• Drug Development

  Stealth BioTherapeutics Initiates Phase III Study of Elamipretide in Patients with Primary Mitochondrial Myopathy

  Pivotal trial to evaluate treatment for disease with no FDA-approved treatment options

  November 6, 2017

   · 

  3 min read
• BioMidwest

  Moleculera Labs Issued Key U.S. Patent Covering the Company’s Diagnostic Panel for Infection-Induced Autoimmune Neuropsychiatric Disorders

  Moleculera Labs, today announced that a key patent has issued covering the company’s Cunningham Panel and its use in helping physicians identify whether an individual’s neurologic and/or psychiatric symptoms could be caused by an autoimmune dysfunction.

  November 6, 2017

   · 

  2 min read
• Treatments Commence at Two Algerian Hospitals Equipped with Modern Varian Radiotherapy Systems

  reatments delivered using linear accelerators including Algeria’s first TrueBeam systems are being delivered at Sidi-Bel-Abbes and Tlemcen Hospitals in the west of the country.

  November 6, 2017

   · 

  2 min read
• Business

  Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  Rexahn’s cash and investments totaled approximately $23.2 million as of September 30, 2017, compared to approximately $20.3 million as of December 31, 2016.

  November 6, 2017

   · 

  9 min read
• Pharm Country

  Egalet Announces ARYMO ER Added to Large Payer Medicare Part D Formulary

  Egalet today announced that a large payer will provide coverage of ARYMO ER (morphine sulfate) extended-release tablets for oral use -CII for its Medicare Part D members.

  November 6, 2017

   · 

  17 min read
• Business

  Catalent Reports First Quarter Fiscal 2018 Results

  First quarter 2018 revenue of $543.9 million increased 23% as reported and 22% in constant currency from $442.2 million reported in the first quarter a year ago.

  November 6, 2017

   · 

  26 min read
• Bio NC

  Panaceutics to Participate in Personalized Medicine Conference at Harvard Medical School - November 14-16th

  Panaceutics today announced that it has joined the Personalized Medicine Coalition and has been invited to participate in the 13th Annual Personalized Medicine Conference on November 14th through 16th, hosted by Harvard Medical School in Boston, MA.

  November 6, 2017

   · 

  2 min read
• 

  Policy

  Achillion’s ACH-4471 is an Orphan Drug in the U.S. and Europe for PNH

  The EMA Committee for Orphan Medicinal Products also issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH.

  November 6, 2017

   · 

  7 min read
• Business

  Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ Assay in Multiple Myeloma

  Adaptive Biotechnologies announces it has entered into a collaboration agreement with Amgen to utilize Adaptive’s NGS-based clonoSEQ Assay in the Phase 3 CANDOR study.

  November 6, 2017

   · 

  2 min read